Emergent Biosolutions, Inc. (NYSE:EBS) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Monday.

According to Zacks, “Emergent’s key drug BioThrax is from the company’s Biodefense segment. The U.S. government is the primary purchaser of its Biodefense products. Hence, the company’s sole dependence on BioThrax for its revenue is concerning. Moreover, Emergent faces competition from a number of companies with Biodefense products, which could adversely affect the company’s operating results. Shares of the company have underperformed the broader industry so far this year. However, the company’s follow-on contract with the CDC for BioThrax and deals with the BARDA for BioThrax and NuThrax (the next-generation anthrax vaccine candidate) bodes well for growth. NuThrax’s approval will be a huge boost for the company. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has positive record of earnings surprises in recent quarters.”

Separately, BidaskClub upgraded shares of Emergent Biosolutions from a “hold” rating to a “buy” rating in a research report on Saturday, June 24th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $39.25.

Shares of Emergent Biosolutions (EBS) traded down 0.93% during mid-day trading on Monday, hitting $34.18. 106,398 shares of the stock were exchanged. Emergent Biosolutions has a 52 week low of $24.47 and a 52 week high of $36.64. The stock has a market capitalization of $1.40 billion, a price-to-earnings ratio of 27.17 and a beta of 1.21. The stock’s 50-day moving average is $31.90 and its 200-day moving average is $30.97.

Emergent Biosolutions (NYSE:EBS) last released its quarterly earnings data on Thursday, May 4th. The biopharmaceutical company reported $0.23 EPS for the quarter, missing analysts’ consensus estimates of $0.31 by $0.08. Emergent Biosolutions had a net margin of 10.36% and a return on equity of 11.92%. The firm had revenue of $116.90 million during the quarter, compared to the consensus estimate of $121.30 million. During the same quarter last year, the business posted $0.16 earnings per share. Emergent Biosolutions’s revenue was up 13.5% compared to the same quarter last year. Analysts forecast that Emergent Biosolutions will post $1.58 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was reported by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/07/17/emergent-biosolutions-inc-ebs-stock-rating-lowered-by-zacks-investment-research.html.

Large investors have recently made changes to their positions in the stock. Norges Bank bought a new stake in shares of Emergent Biosolutions during the fourth quarter valued at about $12,364,000. Aberdeen Asset Management PLC UK increased its position in Emergent Biosolutions by 29.6% in the first quarter. Aberdeen Asset Management PLC UK now owns 1,618,576 shares of the biopharmaceutical company’s stock valued at $47,003,000 after buying an additional 369,908 shares during the period. Vanguard Group Inc. increased its position in Emergent Biosolutions by 6.7% in the first quarter. Vanguard Group Inc. now owns 3,773,200 shares of the biopharmaceutical company’s stock valued at $109,574,000 after buying an additional 238,194 shares during the period. State Street Corp increased its position in Emergent Biosolutions by 17.2% in the first quarter. State Street Corp now owns 1,452,472 shares of the biopharmaceutical company’s stock valued at $42,180,000 after buying an additional 213,500 shares during the period. Finally, Snyder Capital Management L P increased its position in Emergent Biosolutions by 17.8% in the first quarter. Snyder Capital Management L P now owns 1,134,332 shares of the biopharmaceutical company’s stock valued at $32,941,000 after buying an additional 171,636 shares during the period. Institutional investors and hedge funds own 85.89% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).

Get a free copy of the Zacks research report on Emergent Biosolutions (EBS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Emergent Biosolutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions Inc. and related companies with MarketBeat.com's FREE daily email newsletter.